Single PSMA PET positive bone metastasis from prostate carcinoma

Według
  • Dr Bjoern Jobke

Data publikacji: 1 lutego 2016 | Uaktualniono dnia 22 lutego 2016

Report

Diagnosis

Single PSMA PET positive bone metastasis from prostate carcinoma

History

  • 80 yo male patient with a history of prostate cancer 6 yrs. ago
  • Gleason 7b (4+3)
  • Primary staging T3 N0 M0
  • Local radiation treatment
  • Initial PSA 148ng/ml; Nadir: 14 ng/ml, recent: 1,76 ng/ml

 

Findings

  • Focal PSMA PET (68Ga-PSMA-11 tracer) uptake in the distal sternum (red indicating high uptake, or accumulation during secretion) @2.5   @3.3
  • The lesion is not visible on nativ CT, no osteodestruction is present @5.35  
  • Coronal T2 HASTE barely shows the hypointens lesion in the sternum @4.3
  • Fused PET CT and MR images make the lesion in the sternum easily visibly @1.4 

DDx

  • The PSMA tracer is highly specific thus DDx are not evident
  • Occasionally, lesions with high vascularization (e.g. hemangioma) may mimic PSMA uptake 

Discussion

  • Prostate Cancer (PC) metastasizes predominantly to lymph nodes (LNs) and bone in the initial metastatic stages, followed by liver and lung metastases in later stages. Prostate-specific membrane antigen (PSMA) is a cell surface protein which is significantly overexpressed in PC cells compared to other PSMA expressing tissues such as the kidney, proximal small intestine, salivary glands and the neovasculature of several solid tumours.
  • Positiv PSMA PET uptake in lymph nodes and bone  is always highly suspicous for metastastic disease. 
  • Hybrid imaging technology facilitates sensitivity for lesional findings and correlation with morphology in CT or MR.

Key points

  • PSMA PET in patients with prostate cancer significantly increases sensitivity for nodal or osseous metastases.

References

Comparison of hybrid (68)Ga-PSMA PET/MRI and (68)Ga-PSMA PET/CT in the evaluation of lymph node and bone metastases of prostate cancer.

Freitag MT, Radtke JP, Hadaschik BA, Kopp-Schneider A, Eder M, Kopka K, Haberkorn U, Roethke M, Schlemmer HP, Afshar-Oromieh A.

Eur J Nucl Med Mol Imaging. 2016 Jan;43(1):70-83. doi: 10.1007/s00259-015-3206-3. Epub 2015 Oct 28